At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone
In Brief
A Phase 3 clinical trial evaluating Cediranib, Lomustine Chemotherapy, and 1 other intervention for Recurrent Glioblastoma. Completed, enrolled 423 participants across 62 sites in 10 countries.
Detailed Summary
The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has not yet been approved for this disease. This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo ("inactive substance") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.
Study Details
Timeline
Interventions
30 mg/day, oral, until progression
20 mg/day, oral, until progression
110 mg/m2 / Q6W, oral, until progression
Oral, until progression